Activation_NN
of_IN
NF-kappa_NN
B_NN
by_IN
interleukin_NN
2_CD
in_IN
human_JJ
blood_NN
monocytes_NNS
._.

We_PRP
report_VBP
here_RB
that_IN
interleukin_NN
2_CD
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
acts_VBZ
on_IN
human_JJ
blood_NN
monocytes_NNS
by_IN
enhancing_VBG
binding_NN
activity_NN
of_IN
the_DT
transcription_NN
factor_NN
NF-kappa_NN
B_NN
to_TO
its_PRP$
consensus_NN
sequence_NN
in_IN
the_DT
5_CD
'_``
regulatory_JJ
enhancer_NN
region_NN
of_IN
the_DT
IL-2_NN
receptor_NN
alpha_NN
chain_NN
-LRB-_-LRB-
p55_NN
-RRB-_-RRB-
._.

Similarly_RB
,_,
IL-2_NN
activates_VBZ
NF-kappa_NN
B_NN
in_IN
the_DT
human_JJ
monocytic_JJ
cell_NN
line_NN
U_NN
937_CD
,_,
but_CC
not_RB
in_IN
resting_VBG
human_JJ
T-cells_NNS
._.

This_DT
effect_NN
is_VBZ
detectable_JJ
within_IN
15_CD
min_NN
and_CC
peaks_VBZ
1_CD
h_NN
after_IN
exposure_NN
to_TO
IL-2_NN
._.

Enhanced_VBN
NF-kappa_NN
B_NN
binding_NN
activity_NN
is_VBZ
followed_VBN
by_IN
functional_JJ
activation_NN
in_IN
that_WDT
inducibility_NN
of_IN
the_DT
IL-2_NN
receptor_NN
alpha_NN
chain_NN
is_VBZ
mediated_VBN
by_IN
enhanced_VBN
NF-kappa_NN
B_NN
binding_NN
and_CC
that_IN
a_DT
heterologous_JJ
promoter_NN
containing_VBG
the_DT
NF-kappa_NN
B_NN
consensus_NN
sequence_NN
-LRB-_-LRB-
-291_CD
to_TO
-245_CD
-RRB-_-RRB-
of_IN
the_DT
IL-2_NN
receptor_NN
alpha_NN
chain_NN
gene_NN
is_VBZ
activated_VBN
._.

In_IN
addition_NN
,_,
IL-2_NN
is_VBZ
capable_JJ
of_IN
increasing_VBG
transcript_NN
levels_NNS
of_IN
the_DT
p50_NN
gene_NN
coding_VBG
for_IN
the_DT
p50_NN
subunit_NN
of_IN
the_DT
NF-kappa_NN
B_NN
transcription_NN
factor_NN
,_,
whereas_IN
mRNA_NN
levels_NNS
of_IN
the_DT
p65_NN
NF-kappa_NN
B_NN
gene_NN
remained_VBD
unchanged_JJ
._.

